Company News: AstraZeneca

Share this article:
The FDA approved Crestor for use in patients who are not currently suffering from heart disease but who may be considered at-risk based on age (50 and over for men, 60 and over for women), elevated CRP levels and at least one other risk factor, including smoking, hypertension, low HDL-C or family history of early heart disease. In observance of the PhRMA guiding principles on DTC, the brand will defer consumer advertising on the expanded label for awhile while reps detail doctors on it first. Messaging around the brand's unique indication for slowing the progression of atherosclerosis will continue to be a key part of the brand's overall message, said an AstraZeneca spoke.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.